Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013

American Journal on Addictions

Volumn 24, Issue 1, 2015, Pages 24-29

  Turner, Lydia ^a   Kruszewski, Stefan P ^a,b   Alexander, G Caleb ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Stefan P Kruszewski and Associates   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; AMBULATORY CARE; CHILD; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DRUG UTILIZATION; GENERAL PRACTITIONER; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL SPECIALIST; MIDDLE AGED; OPIATE ADDICTION; PHYSICIAN; PRESCRIPTION; PSYCHIATRIST; QUANTITATIVE ANALYSIS; REVIEW; SCHOOL CHILD; UNITED STATES; VERY ELDERLY; FEMALE; OPIOID-RELATED DISORDERS; TRENDS;

AMBULATORY CARE; ANALGESICS, OPIOID; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 84961373718     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12174     Document Type: Review

References (43)

1. Center for substance abuse treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) series 43. HHS publication no. (SMA) 12-4214. Rockville, MD: Substance abuse and mental health services administration, 2005.
2. Courtwright DT,. Dark paradise: A history of opiate addiction. Cambridge, MA: Harvard University Press, 1982, expanded edition 2001.
3. Compton WM, Volkow ND,. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend. 2006; 81: 103-107.
4. Manchikanti L, Singh A,. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008; 11: S63-S88.special issue.
5. Substance abuse and mental health services administration. Drug abuse warning network: Selected tables of national estimates of drug-related emergency department visits. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA; 2010.
6. Johnston LD, O'Malley PM, Bachman, et al. Monitoring the future: National results on adolescent drug use overview of key findings. http://monitoringthefuture.org/pubs/monographs/mtf-overview2011.pdf
7. Results from the 2012 National Survey on Drug Use and Health: Summary of national findings. Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm (Accessed October 8, 2013).
8. Alexander GC, Kruszewski SP, Webster DW,. Rethinking opioid prescribing to protect patient safety and public health. JAMA In press.
9. Calcaterra S, Glaz J, Binswanger IA,. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013; 131: 263-270.
10. Dole VP, Nyswander M,. A medical treatment for diacetylmorphine (heroin) addiction: A clinical train with methadone hydrochloride. JAMA 1965; 193: 646-650.
11. Rettig RA, Yarmolinsky A. Federal regulations of methadone treatment. IOM Report 1995. Available at: http://www.nap.edu/catalog/4899.html
12. Jaffe JH, O'Keeffe C,. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003; 70 (2 suppl): S3-S11.
13. Subutex and suboxone approved to treat opioid dependence. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191521.htm (Accessed January 30, 2014).
14. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994; 55: 569-580.
15. Chiang CN, Hawks Rl,. Pharmacokinetics of the comination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70:(Suppl.): S39-S47.
16. Fiellin DA, O'Connor PG,. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347: 817-823.
17. Barnett PG,. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009; 104: 982-992.
18. Stein BD, Gordon AJ, Sorbero M, et al. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012; 123: 72-78.
19. Mark TL, Kassed CA, Vandivort-Warren R, et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2005; 99: 345-349.
20. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/Researchers/NDTI-Brief.pdf.
21. Stafford RS, Radley DC,. The underutilization of cardiacmedications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003; 41: 56-61.
22. Higashi AS, Zhu S, Stafford RS, et al. National trends in outpatient asthma treatment, 1997-2009. J Gen Intern Med. 2011; 26: 1465-1470. Epub 2011 Jul 16.
23. Zell ER, McCaig LF, Kupronis BA, et al. A comparison of the national disease and therapeutic index and the national ambulatory medical care survey to evaluate antibiotic usage. Proceedings of the section on survey research methods, American Statistical Association. Alexandria, VA: American Statistical Association. 2000;840-845.
24. Anstice S, Strike CJ, Brands B,. Supervised methadone consumptions: Client issues and stigma. Subst Use Misuse. 2009; 44: 797-808.
25. Gunderson EW, Fiellin DA,. Office-based maintenance treatment of opioid dependence: How does it compare with traditional approaches? CNS Drugs 2008; 22: 99-111.
26. Subutex and suboxone approved to treat opioid dependence. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191521.htm (Accessed January 30, 2014).
27. Arfken CL, Johanosn CE, Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse. 2010; 39: 96-104.
28. Monte AA, Mandel T, Wilford BB, et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28: 226-231.
29. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11: 1078-1091.
30. Maremmani I, Gerra G,. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment. Am J Addict. 2010; 19: 557-568.
31. West SL, O'Neal KK, Graham CW,. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse. 2000; 12: 405-414.
32. Gossop M, Marsden J, Stewart D, et al. The national treatment outcome research study (NTORS): 4-5 year follow-up results. Addiction. 2003; 98: 291-303.
33. Fischer B, Rehm J, Kim G, et al. Eyes wide shut? A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res. 2005; 11: 1-9.
34. Vester A,. Buning Buprenorphine: E. Critical questions examined. Amsterdam, Netherlands. Euro-methworks. 2005; 1-38.
35. Barnett PG, Rodgers JH, Bloch DA,. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001; 96: 683-690.
36. Finch JW, Kamien JB, Amass L,. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependcen within a private practice setting. J Addict Med. 2007; 104-110.
37. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. Am J Addict. 2008; 17: 116-120.
38. Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination table (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev. 2004; 23: 311-317.
39. http://www.naabt.org/tl/buprenorphine-suboxone-treatment.cfm.
40. Rosenheck R, Kosten T,. Buprenorphine for opiate addition: Potential economic impact. Drug Alcohol Depend. 2001; 63: 253-262.
41. Johanson C, Arken CL, di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012; 120: 190-195.
42. Mitchell SG, Kelly SM, Brown BS, et al. Use of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009; 18: 346-355.
43. Kuehn BM,. Easy to use overdose antidote earns fast-track approval. JAMA. 2014; 311: 1600.